BP
FDMT icon

Ballentine Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

Ballentine Partners’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$218K Hold
16,359
– – ﹤0.01% 971
2026
Q1 		$152K Sell
16,359
-170
-1% -$1.48K ﹤0.01% 965
2025
Q4 		$124K Buy
16,529
+170
+1% +$1.72K ﹤0.01% 959
2025
Q3 		$142K Buy
+16,359
New +$97.8K ﹤0.01% 956

Other funds holding FDMT

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
APW
Allied Private Wealth Boca Raton, Florida $156M AUM
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Ballentine Partners's FDMT Position: Q2 2026 in Review

Ballentine Partners held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 16,359 shares worth $218K. The position accounts for ﹤0.01% of the portfolio, ranked #971.

Ballentine Partners first reported a position in FDMT in Q3 2025 and has held it in 4 quarters since. 9 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Ballentine Partners held 16,359 shares of 4D Molecular Therapeutics worth $218K as of Q2 2026.
  • Ballentine Partners left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #971 holding.
  • Ballentine Partners first reported a position in 4D Molecular Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 9 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.